SCHEMBL10285998

SCHEMBL10285998

CCC(COC(C)C)OC(C)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
PRKCA P17252 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
TBXA2R P21731 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
GALR3 O60755 1/20 0.35
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
LMNA P02545 3/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
HRH1 P35367 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
SLC18A3 Q16572 1/20 0.34
DAGLA Q9Y4D2 1/20 0.33
PGD P52209 1/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4808933 0.83 PRKCA (0.47) TSHRPRKCA
SCHEMBL11286608 0.82 TDP1 (0.46) TSHRPRKCACHRM2CHRM4CHRM1
SCHEMBL13118195 0.81 TSHR (0.44) TSHRDAGLAALDH1A1
SCHEMBL1584634 0.79
SCHEMBL5192564 0.78 TDP1 (0.50) TSHRPRKCASMN1; SMN2LMNAMEN1
SCHEMBL4567273 0.78 PRKCA (0.42) TSHRPRKCACHRM2CHRM4CHRM1
SCHEMBL5190999 0.78 TDP1 (0.50) TSHRPRKCASMN1; SMN2LMNAMEN1
SCHEMBL425452 0.78 TDP1 (0.50) TSHRPRKCASMN1; SMN2LMNAMEN1
SCHEMBL27291950 0.78 PRKCA (0.42) TSHRPRKCACHRM2CHRM4CHRM1
SCHEMBL25144614 0.77 TSHR (0.40) TSHRCHRM2CHRM4CHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11693310-B2 Blue curable resin composition, blue color filter, and display device including same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-07-04 US disclosed
US-9051397-B2 Oxime ester BASF SE (DE) 2015-06-09 US disclosed
US-9051397-B2 Oxime ester BASF SE (DE) 2015-06-09 US disclosed
EP-2625166-B1 OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS BASF SE (DE) 2014-09-24 EP disclosed
US-20130188270-A1 OXIME ESTER BASF SE (DE) 2013-07-25 US disclosed
US-20130188270-A1 OXIME ESTER BASF SE (DE) 2013-07-25 US disclosed
WO-2012045736-A1 OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS BASF SE (DE) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130188270-A1 OXIME ESTER CBR3, CBR1, COX15 TSHR 521/4885PRKCA 4850/4885CHRM2 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.